The goal of this project, since its inception, has been to characterize the effects of T cells with Fc receptors on the growth and differentiation of myeloma tumor cells. Previous studies have shown that mice and patients with myeloma tumors develop a marked expansion of circulating suppressor T cells that bear on their surfaces isotype-specific Fc receptors. These FcR+ suppressor T cells produce a suppressor factor that binds to immunoglobulin (immunoglobulin-binding factor - IBF). We have shown that this IBF can suppress the growth and differentiation of myeloma tumor cells. IBF binds to surface immunoglobulin on myeloma cells and can suppress proliferation of tumor cells. In addition, IBF can also suppress the transcription of immunoglobulin genes by suppressing the function of immunoglobulin enhancers. Using the murine myeloma, MOPC-315 as a target and IgA-binding factor (IgABF - from T cells with IgA-Fc receptors) we herein propose to study the molecular mechanism of this response and: 1) Examine the effect of IgABF on early activation biochemical events associated with binding of IgABF to surface immunoglobulin on myeloma tumor cells. 2) Identify cis acting DNA sequences, within the immunoglobulin heavy chain enhancer, that are important in modulating the effects of IgABF. 3) Identify trans acting proteins, that bind to the sequences identified in specific aim #2, and modulate the effects of IgABF. These studies will contribute to our understanding of immunoglobulin- binding factors and the immunobiology of myeloma. In addition, these studies will contribute to our understanding of the control of B cell proliferation and the production of immunoglobulin by B cells.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA041165-08
Application #
3181440
Study Section
Experimental Immunology Study Section (EI)
Project Start
1990-02-01
Project End
1994-06-30
Budget Start
1992-07-01
Budget End
1993-06-30
Support Year
8
Fiscal Year
1992
Total Cost
Indirect Cost
Name
University of Arkansas for Medical Sciences
Department
Type
Schools of Medicine
DUNS #
City
Little Rock
State
AR
Country
United States
Zip Code
72205
Grigorieva, I; Grigoriev, V G; Rowney, M K et al. (2000) Regulation of c-myc transcription by interleukin-2 (IL-2). Identification of a novel IL-2 response element interacting with STAT-4. J Biol Chem 275:7343-50
Hoover, R G; Lary, C; Page, R et al. (1995) Autoregulatory circuits in myeloma. Tumor cell cytotoxicity mediated by soluble CD16. J Clin Invest 95:241-7
Epstein, J; Hoover, R; Kornbluth, J et al. (1995) Biological aspects of multiple myeloma. Baillieres Clin Haematol 8:721-34
Moore, J S; Hoover, R G (1989) Defective isotype-specific regulation of IgA anti-erythrocyte autoantibody-forming cells in NZB mice. J Immunol 142:4282-8
Moore, J S; Prystowsky, M B; Hoover, R G et al. (1988) Defective T cell-mediated, isotype-specific immunoglobulin regulation in B cell chronic lymphocytic leukemia. Blood 71:1012-20
Kornbluth, J; Hoover, R G (1988) Changes in gene expression associated with IFN-beta and IL-2-induced augmentation of human natural killer cell function. J Immunol 141:3234-40
Roman, S; Moore, J S; Darby, C et al. (1988) Modulation of Ig gene expression by Ig binding factors. Suppression of alpha-H chain and lambda-2-L chain mRNA accumulation in MOPC-315 by IgA-binding factor. J Immunol 140:3622-30
Sukhatme, V P; Kartha, S; Toback, F G et al. (1987) A novel early growth response gene rapidly induced by fibroblast, epithelial cell and lymphocyte mitogens. Oncogene Res 1:343-55
Broome, H E; Reed, J C; Godillot, E P et al. (1987) Differential promoter utilization by the c-myc gene in mitogen- and interleukin-2-stimulated human lymphocytes. Mol Cell Biol 7:2988-93